Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry

Diabetes, Obesity and Metabolism

Volumn 19, Issue 10, 2017, Pages 1416-1424

  Fadini, Gian Paolo ^a   Saragoni, Stefania ^c   Russo, Pierluigi ^b   Degli Esposti, Luca ^c   Vigili de Kreutzenberg, Saula ^a   Melazzini, Mario ^b   Avogaro, Angelo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b ITALIAN MEDICINES AGENCY   (Italy)

^c Economics and Outcomes Research   (Italy)

Author keywords

antidiabetic drug; cardiovascular disease; DPP 4 inhibitor; observational study; sulphonylureas; type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; DISEASE REGISTRY; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; POISSON DISTRIBUTION; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; CLASSIFICATION; COMPLICATION; DIABETIC ANGIOPATHY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; REGISTER; RISK FACTOR;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 85020080648     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12979     Document Type: Article

References (33)

1. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
2. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2015;3:356-366.
3. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370:1129-1136.
4. Tang WH, Francis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol. 2003;41:1394-1398.
5. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-1326.
6. Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232-242.
7. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327-1335.
8. Food and Drug Administration. FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. 2016. https://www.fda.gov/Drugs/DrugSafety/ucm486096.htm. Accessed May 5 2017.
9. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014;24:689-697.
10. Cebrian-Cuenca AM, Orozco-Beltran D, Navarro-Perez J, Franch-Nadal J, Nunez-Villota J, Consuegra-Sanchez L. Saxagliptin and risk of heart failure hospitalisation: concern or miscalculation? Int J Cardiol. 2016;220:573-574.
11. Fadini GP, Albiero M, Avogaro A. Direct effects of DPP-4 inhibition on the vasculature. Reconciling basic evidence with lack of clinical evidence. Vascul Pharmacol. 2015;73:1-3.
12. Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol. 2011;55:10-16.
13. Takada S, Masaki Y, Kinugawa S, et al. Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling. Cardiovasc Res. 2016;111:338-347.
14. Kubota A, Takano H, Wang H, et al. DPP-4 inhibition has beneficial effects on the heart after myocardial infarction. J Mol Cell Cardiol. 2016;91:72-80.
15. Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging. 2010;3:195-201.
16. Devin JK, Pretorius M, Nian H, Yu C, Billings FT, Brown NJ. Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition. Hypertension. 2014;63:951-957.
17. White WB, Wilson CA, Bakris GL, et al. Angiotensin-converting enzyme inhibitor use and major cardiovascular outcomes in type 2 diabetes mellitus treated with the dipeptidyl peptidase 4 inhibitor alogliptin. Hypertension. 2016;68:606-613.
18. Li L, Li S, Deng K, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ. 2016;352:i610.
19. Fadini GP, Avogaro A, Degli Esposti L, et al. Risk of hospitalisation for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. Eur Heart J. 2015;36:2454-2462.
20. Pantalone KM, Kattan MW, Yu C, et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol. 2009;46:145-154.
21. Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339:b4731.
22. Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32:1900-1908.
23. Degli Esposti L, Saragoni S, Sangiorgi D, Buda S, Cangini A, Russo P. The Nationwide Osmed Health-Db Database. A tool to support healthcare decision-making and real-world evidence generation. Value Health. 2015;18:A693.
24. Avogaro A, Fadini GP, Sesti G, Bonora E, Del Prato S. Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. Cardiovasc Diabetol. 2016;15:111.
25. Chang CH, Chang YC, Lin JW, et al. No increased risk of hospitalisation for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan. Int J Cardiol. 2016;220:14-20.
26. Fu AZ, Johnston SS, Ghannam A, et al. Association between hospitalisation for heart failure and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: an observational study. Diabetes Care. 2016;39:726-734.
27. Toh S, Hampp C, Reichman ME, et al. Risk for hospitalized heart failure among new users of Saxagliptin, Sitagliptin, and other antihyperglycemic drugs: a retrospective cohort study. Ann Intern Med. 2016;164:705-714.
28. Raschi E, Poluzzi E, Koci A, Antonazzo IC, Marchesini G, De Ponti F. Dipeptidyl peptidase-4 inhibitors and heart failure: analysis of spontaneous reports submitted to the FDA adverse event reporting system. Nutr Metab Cardiovasc Dis. 2016;26:380-386.
29. Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579-1588.
30. McGuire DK, Van de Werf F, Armstrong PW, et al. Association between sitagliptin use and heart failure hospitalisation and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016;1:126-135.
31. Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385:2067-2076.
32. Andersson C, Gislason GH, Jorgensen CH, et al. Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure. Diabetes Res Clin Pract. 2011;94:119-125.
33. Verlato G, Muggeo M, Bonora E, Corbellini M, Bressan F, de Marco R. Attending the diabetes center is associated with increased 5-year survival probability of diabetic patients: the Verona Diabetes Study. Diabetes Care. 1996;19:211-213.